Pharmacogenomics of Asparaginase Induced Hepatotoxicity
Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Jun 14, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how genetic factors may affect the risk of liver damage in patients with a type of blood cancer called acute lymphoblastic leukemia (ALL) who are receiving a medication called asparaginase. Asparaginase is an important part of the treatment for ALL, but it can sometimes harm the liver. By testing saliva samples, researchers hope to identify specific genetic markers that might help predict how well patients will tolerate this medication.
To be eligible for this trial, participants must be newly diagnosed with ALL and have not received any prior treatment. They should also be starting asparaginase as part of their treatment plan. If you or a loved one is interested in participating, it's important to know that you will need to be able to understand the study and provide written consent. The trial is currently recruiting participants, and if you have received asparaginase in the past at the University of Southern California between 2012 and 2017, you may also be able to take part in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL
- • Receiving asparaginase as part of the primary treatment regimen
- • Ability to understand and the willingness to sign a written informed consent
- • For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)
- Exclusion Criteria:
- • Patients who are unable to give informed consent
About University Of Southern California
The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Houda Alachkar, Ph.D.
Principal Investigator
University of Southern California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials